Editorial

The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain

Roy Eldor, Itamar Raz

Manuscript submitted April 21, 2009; resubmitted May 17, 2009; accepted May 19, 2009.

Keywords: diabetes, cardiovascular disease, obesity, weight gain, glycemic control, ACCORD, UKPDS

Abstract

Both the DCCT and UKPDS trials demonstrated that improved glycemic control reduces microvascular complications. Inconclusive evidence, however, has remained on the question of the effect of glycemic control on macrovascular disease (with special emphasis on cardiovascular morbidity and mortality). In the last year, the data from four large trials were published, directly addressing this question (ACCORD, ADVANCE, VADT and UKPDS-80), yet the results were conflicting. Close inspection of the structure of three of these trials (ACCORD, ADVANCE and VADT) revealed inadequacies that may explain the unfavorable results, such as the inclusion of mainly elderly patients with previous macrovascular complications. It is not surprising that intensive glycemic control resulted in a rise of hypoglycemic events yet did not decrease macrovascular morbidity or mortality in these cohorts. On the other hand, the UKPDS-80 trial, a follow-up of the original UKPDS, showed that intensive glycemic control was beneficial when initiated in newly diagnosed patients. These results led us to develop a new individualized method of determining the target HbA1c based on the characteristics of the individual. This method considers the patient’s possible benefit from glycemic control, the risk of suffering hypoglycemic events and consequences suffered from the hypoglycemic event. It is essential that the target HbA1c be tailored to the patient, with different goals set for the recently diagnosed “healthy” and young patient on the one hand, and the elderly patient with co-morbidities and polypharmacy on the other hand. We further suggest a method of comparing and choosing between the different hypoglycemic drugs available. Drugs should be considered not only based on their hypoglycemic effect but also on several other attributes such as effects on weight, glycemic durability, cardiovascular protection, individual experience with the drug, method of delivery and side effect profiles. Scoring the different attributes allows us to compare between different preparations and choose the most suitable drugs for each individual patient. Using our newly suggested system, a physician will first calculate the adequate HbA1c goal for his patient and then choose the drug that will best suit him, thus tailoring the treatment to the patients needs.

Fulltext: HTML , PDF (293KB)

This article has been cited by other articles:

	Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A Diabetes Technol Ther 2012. In press
	Role of incretin therapy at various stages of diabetes Cernea S Rev Diabet Stud 2011. 8(3):323-338
	Intensive glycemic control and cardiovascular disease: Are there patients who may benefit? Chokrungvaranon N, Deer J, Reaven PD Postgrad Med 2011. 123(6):114-123
	The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus Asche CV, Bode B, Busk AK, Nair S Diabetes Obes Metab 2011. In press
	Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus Garber AJ J Am Osteopath Assoc 2011. 111(7 Suppl 5):S20-S30
	Intervention at the very early stage of type 2 diabetes Aizawa T, Funase Y Diabetologia 2011. 54(3):703-704
	Diabetes and cardiovascular disease Bloomgarden ZT Diabetes Care 2011. 34(3):e24-30
	Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous healthcare service, a new medical information system Lim S, Kang SM, Shin H, Lee HJ, Won Yoon J, Yu SH, Kim SY, Yoo SY, Jung HS Park KS, Ryu JO, Jang HC Diabetes Care 2011. 34(2):308-333
	Management of type 2 diabetes: more evidence is required to address the clinical and contextual facets Hernandez-Jimenez S, Aguilar-Salinas CA, Mehta R, Rull JA, Gomez-Perez FJ Curr Diabetes Rev 2011. 7(2):99-105
	Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes Bweir S, Al-Jarrah M, Almalty AM, Maayah M, Smirnova IV, Novikova L, Stehno-Bittel L Diabetol Metab Syndr 2009. 1(1):27